DGAP-News: Novel Pain Treatment is Now Available: iovera System Harnesses the Power of Cold to Block Pain

        Print
| Source: EQS Group AG
DGAP-News: myoscience /
Novel Pain Treatment is Now Available: iovera System Harnesses the
Power of Cold to Block Pain

01.05.2014 / 14:00

---------------------------------------------------------------------

REDWOOD CITY, Calif., 2014-05-01 14:00 CEST (GLOBE NEWSWIRE) --
California based myoscience, inc., is pleased to announce the launch of the
revolutionary iovera* health treatment, a new option to immediately block pain
using the body's natural response to cold without the use of drugs or surgery. 

Vinod Dasa, MD, Associate Professor of Orthopaedic Surgery in New Orleans, one
of the first to perform the treatment has treated over 50 patients and is
excited about the possibilities. 'I think this technology has the potential to
change the current paradigm of acute and chronic pain management. The patients
that I have treated are all grateful to have an option that is very safe and
that has allowed them to get back to functionality quickly.' 

Clint Carnell, CEO of myoscience, has witnessed the powerful patient outcomes
'It's rewarding to provide this revolutionary treatment to patients suffering
from pain. We have developed a product that delivers a treatment that is safe,
effective and most importantly free of the negative systemic side effects often
common with today's therapeutic options.' 

The iovera* health treatment utilizes myoscience's platform technology, the
Focused Cold Therapy(TM) delivery system, to precisely target peripheral
nerves, temporarily interrupting pain signaling pathways. This precise cold
treatment causes a reversible nerve block based on a process called 2nd degree
degeneration that is followed by a predictable restoration of nerve function.
The iovera* system offers patients a new treatment option, with no systemic
side effects and nothing being injected into the body. Most patients experience
instant pain relief after an iovera* treatment, with results that can last up
to three months. 

For physicians and patients who would like additional information, please visit
www.ioverahealth.com or email us directly at contact@myoscience.com. 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy, the
standard of care for the treatment of peripheral nerve conditions. Focused Cold
Therapy is the patented technology delivered by the iovera:o system. The
iovera:o 
system is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions,
and is indicated in the United States for use in pain management and general
surgical use. For more information, please visit www.myoscience.com. 

The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581 

(c) 2014 myoscience. All rights reserved. iovera* and Focused Cold Therapy are
trademarks of myoscience. 


         CONTACT: 1600 Seaport Blvd., Ste. 450 / Redwood City, CA
         Tel: 650.474.2600 / iovera.com
         
         MEDIA RELATIONS
         Jay Patel / myoscience@hypertonic.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

01.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     myoscience     
 
 
             United States  
ISIN:        US9902131674   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
266038 01.05.2014